News Protalix BioTherapeutics, Inc.

Stocks

PLX

US74365A3095

Pharmaceuticals

Market Closed - NYSE Other stock markets 16:00:00 2026-06-18 EDT			5-day change	1st Jan Change
2.220 ^USD	+9.90%		+6.22%	+23.33%

05-13	Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026
05-13	Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

All News

Mentions Relevance

05-13	Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026
05-13	Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Protalix BioTherapeutics : PLX Corporate Presentation (May 2026)	PU
05-13	Protalix: Q1 Earnings Snapshot	AQ
05-13	Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results	PR
05-13	Protalix BioTherapeutics, Inc. Reaffirms Revenue Guidance for the Year 2026	CI
05-06	Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026	PR
03-18	Chiesi Global Rare Diseases and Protalix Biotherapeutics Announces European Commission Approval of an Add-On Every Four Weeks Dosing Regimen for Pegunigalsidase Alfa	CI
03-18	Top Midday Decliners	MT
03-18	Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-18	Protalix BioTherapeutics, Inc., 2025 Earnings Call, Mar 18, 2026
03-18	Protalix BioTherapeutics, Inc. Provides Earnings Guidance for the Year 2026	CI
03-18	Protalix Biotherapeutics reports fiscal year 2025 financial and business results	RE
03-18	Protalix: Q4 Earnings Snapshot	AQ
03-18	Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results	PR
03-11	Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026	PR
03-09	EU approves four-week dosing option for Chiesi and Protalix's Elfabrio	RE
03-09	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)	AQ
03-09	Chiesi Global Rare Diseases and Protalix Biotherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio	CI
02-11	Protalix BioTherapeutics : PLX Corporate Presentation (February 2026)	PU
01-30	Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. Receive Positive CHMP Opinion for Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio (pegunigalsidase alfa) ? in EU	CI
01-30	Protalix Fabry Disease Treatment Recommended for Approval by EMA Committee	MT
01-30	Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU	AQ
01-05	Protalix BioTherapeutics Letter to Stockholders	PR
12-17	Protalix Partners With Secarna to Jointly Develop Therapies for Rare Renal Indications	MT